Nasdaq · Biotech stocks database

ABVX — Abivax SA

ABVX (Abivax SA) stock: $105.04, $9.04B market cap, $1.26B cash, $7.78B EV, $10.06B fully diluted market cap. Next expected readout: Dec-26. Lead program: ABX464 (Ulcerative Colitis), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$105.04

Market cap

$9,043.4M

Cash

$1,263.7M

Enterprise value

$7,779.7M

Balance sheet

Cash	$1,263.7M
Debt	$0.0M
Net cash	$1,263.7M
Enterprise value	$7,779.7M
Basic shares	87.2M shares
Fully diluted shares	95.7M shares
Fully diluted market cap	$10,056.8M
Cash per share	$14.50

Cash figures as of 2026-07-06. Database snapshot: 2026-09-21.

Price history

Loading ABVX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Obefazimod 50 mg Capsule	Phase 1	Healthy	—
Jan 12 - Feb 23	Obefazimod	Phase 2	Moderately to Severely Active Crohn Disease	—
Apr 12 - May 24	ABX464	Phase 2	Ulcerative Colitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	ABX464
Lead indication	Ulcerative Colitis
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05535946	Phase 3	Active, not recruiting	Sponsor	ABVX	—	Ulcerative Colitis	—
NCT06456593	Phase 2	Recruiting	Sponsor	ABVX	—	Moderately to Severely Active Crohn Disease	—
NCT05177835	Phase 2	Active, not recruiting	Sponsor	ABVX	—	Ulcerative Colitis	—
NCT03897543	Phase 2	Recruiting	Sponsor	ABVX	—	Carcinoma, Hepatocellular	—
NCT07453784	Phase 1	Recruiting	Sponsor	ABVX	—	Healthy	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Abivax S.A. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,804,703	+410,684	11.30%	2026-08-14
Logos Global Management	1,024,000	+349,000	5.87%	2026-08-14
OrbiMed Advisors	546,522	+80,822	1.38%	2026-08-14
Ikarian Capital	328,635	+271,000	7.10%	2026-08-14
RTW Investments	26,400	+26,400	0.03%	2026-08-14
Baker Bros. Advisors	0	-875,796	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego